Luye Pharma Group Ltd. is an international pharmaceutical company focused on the research, production, and marketing of drugs. The company operates in three primary therapeutic areas: oncology, central nervous system (CNS), and cardiovascular system. Key products include Baituowei (goserelin microspheres) for prostate and breast cancer, Zepzelca (lurbinectedin) for small cell lung cancer, Ruoxinlin (Toludesvenlafaxine Hydrochloride) for major depressive disorder, and ERZOFRI (paliperidone palmitate) for psychiatric conditions. The group develops next-generation candidates such as LY03015, LY03017, and LY03020, alongside biologics from its subsidiary Boan Biotech, including BA1106 and BA1302. Luye Pharma serves markets in multiple countries and regions worldwide, with a significant presence in the PRC and the United States. Strategic partnerships include collaborations with Sinopharm, Shanghai Pharmaceutical, King-Friend, Kexing Biopharm, and Nhwa Pharmaceutical for commercialization and distribution. The company also partners with Jitai Technology for AI-driven drug delivery innovation.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - General Homepage luye.cn
Sector Healthcare IR page —
Tags
oncology, central nervous system, cardiovascular, innovative drugs, biologics, antibodies, adc drugs, mrna vaccines, long-acting injectables, ai drug delivery, Baituowei, Zepzelca, Ruoxinlin, ERZOFRI, Mimeixin, LY03015, LY03017, LY03020, LY01620, BA1106, BA1302, BA1203, BA2201, BA1304, Boan Biotech, Nhwa Pharmaceutical, Sinopharm, SINOPHARM (CNCM LTD), Shanghai Pharmaceutical, King-Friend, Kexing Biopharm, Jitai Technology
Press page —

Metrics

Valuation  
Market cap HK$ 5.79B
Market cap (USD) $ 737.886M
P/E 8.15
PEG 10.69
P/BV 0.27
P/S 0.80
P/OCF 11.18
P/FCF —
Dividend yield —
Turnover / mcap 1.4%
Returns  
ROE 3.6%
ROI 2.5%
ROIC 2.5%
Profit margin 9.8%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 0.76%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 52.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 12.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 6.308B 6.061B 6.143B 5.982B 5.2B 5.54B 6.358B 5.173B 3.815B 2.918B 2.563B 2.544B 2.515B
Net profit 618.747M 471.886M 532.605M 604.807M -134.392M 706.586M 1.469B 1.303B 981.372M 891.539M 754.523M 605.524M 310.498M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 3.41 2.05 3.07 — 3.56 3.82 — 6.16 — — — — —
Price performance 12m 0.7 -0.33 — — 0 — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Luye Pharma Group Ltd. (ticker 2186), listed in Hong Kong.

ETFs Holding Luye Pharma Group Ltd.

ETF Weight in ETF Shares Market value As of
AVEE 0.04% 276,500 $ 54.256K Nov 16, 2026
AVES 0.03% 1,884,000 $ 369.685K Nov 16, 2026
DFEV 0.02% 1,673,500 $ 348.795K Nov 12, 2026
DFSE 0.01% 292,000 $ 60.859K Nov 12, 2026
AVEM 0.01% 16,503,000 $ 3.238M Nov 16, 2026
DFEM 0.01% 3,694,500 $ 770.016K Nov 12, 2026
DFAE 0.00% 2,142,000 $ 446.441K Nov 12, 2026
DFAX 0.00% 248,000 $ 51.689K Nov 12, 2026
AVSE 0.00% 24,000 $ 4,709.36 Nov 16, 2026